Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hemostemix Inc. stock logo
HEM
Hemostemix
C$0.04
C$0.06
C$0.04
C$0.18
C$3.59M0.5546,906 shs103,000 shs
Samsara Inc. stock logo
IOT
Samsara
$38.28
-1.8%
$35.14
$18.05
$40.54
$21.07B1.583.60 million shs2.30 million shs
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
$19.10
+0.1%
$19.10
$18.63
$27.54
$1.91MN/A1,912 shs19,400 shs
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
C$0.08
+14.3%
C$0.08
C$0.07
C$0.25
C$5.79MN/A93,085 shs212,852 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hemostemix Inc. stock logo
HEM
Hemostemix
0.00%0.00%-33.33%-60.00%-73.33%
Samsara Inc. stock logo
IOT
Samsara
-1.78%+9.58%+12.94%+18.06%+102.09%
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
0.00%0.00%0.00%0.00%0.00%
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AN/AN/AN/AN/AN/AN/A
Samsara Inc. stock logo
IOT
Samsara
0.8842 of 5 stars
1.33.00.00.01.94.20.6
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AN/AN/A
Samsara Inc. stock logo
IOT
Samsara
2.56
Moderate Buy$32.60-14.83% Downside
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
0.00
N/AN/AN/A
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest RVV, QPT, IOT, and HEM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Samsara Inc. stock logo
IOT
Samsara
Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$42.00
(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AC$0.00 per share10.77C($0.08) per shareN/A
Samsara Inc. stock logo
IOT
Samsara
$937.39M22.48N/AN/A$1.68 per share22.78
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/AN/AN/AN/AN/A
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/AN/AC$0.03 per share3.18C$0.02 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hemostemix Inc. stock logo
HEM
Hemostemix
-C$2.50M-C$0.04N/AN/AN/AN/A-346.06%5/13/2024 (Estimated)
Samsara Inc. stock logo
IOT
Samsara
-$286.73M-$0.53N/AN/AN/A-30.59%-22.90%-12.81%6/6/2024 (Confirmed)
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/A0.00N/AN/AN/AN/AN/A
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/A-C$0.02N/AN/AN/AN/AN/A6/4/2024 (Estimated)

Latest RVV, QPT, IOT, and HEM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/6/2024N/A
Samsara Inc. stock logo
IOT
Samsara
$0.01N/A-$0.01N/AN/AN/A  
3/7/2024Q4 2024
Samsara Inc. stock logo
IOT
Samsara
-$0.08-$0.08N/A$0.05$258.56 million$276.27 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AN/AN/AN/A
Samsara Inc. stock logo
IOT
Samsara
N/AN/AN/AN/AN/A
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
$0.080.42%N/AN/AN/A
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hemostemix Inc. stock logo
HEM
Hemostemix
N/A
0.11
0.48
Samsara Inc. stock logo
IOT
Samsara
N/A
1.50
1.46
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/AN/A
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/A
6.14
6.03

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Hemostemix Inc. stock logo
HEM
Hemostemix
N/A89.79 millionN/ANot Optionable
Samsara Inc. stock logo
IOT
Samsara
2,895550.52 million186.41 millionNot Optionable
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/A100,000N/ANot Optionable
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/A72.41 millionN/ANot Optionable

RVV, QPT, IOT, and HEM Headlines

SourceHeadline
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVIDRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
tmcnet.com - April 23 at 8:07 AM
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic ProductRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
markets.businessinsider.com - April 18 at 8:03 AM
Revive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDRevive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
finanznachrichten.de - March 27 at 4:23 PM
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDRevive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
finance.yahoo.com - March 27 at 10:10 AM
Revive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDRevive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
finanznachrichten.de - March 19 at 11:42 AM
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDRevive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
markets.businessinsider.com - March 19 at 11:42 AM
Revive Therapeutics Ltd.: Revive Therapeutics Provides Corporate UpdateRevive Therapeutics Ltd.: Revive Therapeutics Provides Corporate Update
finanznachrichten.de - March 12 at 8:23 AM
Revive Therapeutics Provides Corporate UpdateRevive Therapeutics Provides Corporate Update
financialpost.com - March 12 at 7:08 AM
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
markets.businessinsider.com - February 26 at 8:53 PM
Revive Therapeutics Explores the Use of Bucillamine for Long COVIDRevive Therapeutics Explores the Use of Bucillamine for Long COVID
markets.businessinsider.com - February 1 at 9:20 AM
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
markets.businessinsider.com - January 31 at 7:29 PM
Revive Therapeutics Ltd. Announces Offering of Up to $3 MillionRevive Therapeutics Ltd. Announces Offering of Up to $3 Million
financialpost.com - January 24 at 7:03 PM
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development CanadaRevive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
tmcnet.com - January 16 at 8:29 AM
Revive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineRevive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
finanznachrichten.de - January 10 at 2:05 PM
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineRevive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
markets.businessinsider.com - January 10 at 9:05 AM
Travere Therapeutics expects Q4 net product sales from continuing operations to be about $40MTravere Therapeutics expects Q4 net product sales from continuing operations to be about $40M
msn.com - January 8 at 4:03 PM
Revive Therapeutics Announces Results of Annual General and Special Meeting of ShareholdersRevive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
markets.businessinsider.com - December 20 at 5:50 PM
Revive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of BucillamineRevive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of Bucillamine
markets.businessinsider.com - December 18 at 8:03 AM
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of BucillamineRevive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
financialpost.com - December 18 at 7:07 AM
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent ExposureRevive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
markets.businessinsider.com - October 17 at 4:48 PM
Revive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent ExposureRevive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent Exposure
markets.businessinsider.com - October 17 at 11:47 AM
Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentRevive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
finanznachrichten.de - October 11 at 2:48 PM
Revive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentRevive Therapeutics Provides Update of Novel Bucillamine Formulation Development
tmcnet.com - October 11 at 9:47 AM
Revive I-5 project continues with driving surface improvement work starting MondayRevive I-5 project continues with driving surface improvement work starting Monday
komonews.com - October 11 at 12:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Hemostemix logo

Hemostemix

CVE:HEM
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Samsara logo

Samsara

NYSE:IOT
Samsara Inc. provides solutions that connects physical operations data to its connected operations cloud in the United States and internationally. The company's Connected Operations Cloud includes Data Platform, which ingests, aggregates, and enriches data from its IoT devices and has embedded capabilities for AI, workflows and analytics, alerts, API connections, and data security and privacy. Its applications include video-based safety that enables customers to build a safety program and protect their teams with AI-enabled video; vehicle telematics which provides visibility into real-time vehicle location and diagnostics with GPS tracking, routing and dispatch, fuel efficiency management, electric vehicle usage and charge planning, preventative maintenance, and insights to manage fuel and energy costs; and mobile apps and workflows that improves productivity for frontline workers and enables regulatory compliance for workers to see upcoming jobs, capture electronic documents, perform maintenance inspections, maintain compliance logs, and message with back-office administration. The company also provides equipment monitoring which offers visibility and management of unpowered and powered assets, ranging from generators and compressors to heavy construction equipment and trailers to improve operating efficiency, prevent unplanned downtime, and avoid critical safety and compliance issues; and site visibility that provides remote visibility into sites to improve onsite security, safety, and incident response times. It serves transportation, wholesale and retail trade, construction, field services, logistics, utilities and energy, healthcare and education, manufacturing, food and beverage, and other industries, as well as government. Samsara Inc. was incorporated in 2015 and is headquartered in San Francisco, California.
AdvisorShares Q Portfolio Blended Allocation ETF logo

AdvisorShares Q Portfolio Blended Allocation ETF

NYSEARCA:QPT
Revive Therapeutics logo

Revive Therapeutics

CVE:RVV
Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.